Monoclonal Antibody Therapeutics Market (2033): Naked Monoclonal Antibodies, Cancer Treatment & Bispecific Antibody Growth in United States Expansion

DataM Intelligence has released a new research report titled "Monoclonal Antibody Therapeutics Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Monoclonal Antibody Therapeutics market.

Download Sample Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/monoclonal-antibody-therapeutics-market?sindhuri

Recent Key Developments - United States & North America
✅ September 2026: Johnson & Johnson reported new Phase 3 data for RYBREVANT (amivantamab), showing median overall survival of 34.3 months when combined with chemotherapy in first-line EGFR exon 20 insertion-positive NSCLC, compared with 27.9 months for chemotherapy alone. The results reinforce the move toward dual-targeted monoclonal antibody regimens in genetically defined cancer populations.

✅ August 2026: The FDA approved IMAAVY (nipocalimab-aahu), a monoclonal antibody targeting the neonatal Fc receptor (FcRn), as the first approved treatment for warm autoimmune hemolytic anemia. The approval expands antibody therapeutics beyond oncology into rare autoimmune diseases by selectively reducing pathogenic IgG autoantibodies while preserving B-cell function.

✅ July 2026: Sanofi discontinued global regulatory submission plans for amlitelimab, an OX40-ligand monoclonal antibody for atopic dermatitis, after concluding that the overall efficacy and safety evidence did not support further development. The decision highlights increasing pressure on late-stage antibody programs to demonstrate a meaningful advantage over established treatment options.

Recent Key Developments - Japan & Asia-Pacific
✅ September 2026: Johnson & Johnson presented new data for subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) at WCLC 2026, with prophylactic strategies associated with low rates of rash, blood clots and administration-related reactions. The development points toward more convenient subcutaneous delivery models for antibody therapeutics in Asia-Pacific cancer care.

✅ September 2026: Japan approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration across all KEYTRUDA indications already approved in Japan. The expansion demonstrates how antibody treatment is increasingly being adapted from conventional intravenous infusion toward subcutaneous administration.

✅ August 2026: The European Commission approved TECVAYLI (teclistamab) with daratumumab for relapsed/refractory multiple myeloma after at least one prior therapy, while Japan and other Asia-Pacific markets continue to see broader adoption of antibody-based immune therapies. The approval reflects a broader shift toward moving bispecific and combination antibody regimens into earlier treatment lines.

Recent Key Developments - Product & Technology Innovation
✅ 2026: Degrader Antibody Conjugates: Johnson & Johnson completed its $1 billion acquisition of Firefly Bio in July, adding the Firelink degrader antibody conjugate platform designed to deliver targeted protein degraders to cancer cells. The approach extends antibody engineering beyond conventional monoclonal antibodies and ADCs toward intracellular target degradation.

✅ 2026: Subcutaneous Antibody Delivery: Recent approvals and clinical developments around RYBREVANT FASPRO and KEYTRUDA QLEX show increasing emphasis on reformulating established antibody therapies for subcutaneous delivery, potentially reducing infusion-related treatment burdens and changing how biologics are administered in routine care.

✅ 2026: Long-Acting Antibody Engineering: AbbVie completed its acquisition of Apogee Therapeutics in September, adding zumilokibart, a half-life-extended anti-IL-13 monoclonal antibody, along with a long-acting IL-13/TSLP program for inflammatory diseases. The transaction underscores growing interest in antibody designs that extend dosing intervals rather than relying solely on new targets.

List of Key Players 2026:
F. Hoffmann-La Roche Ltd, Novartis AG, Merck & Co. Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, AstraZeneca, Bayer AG, Regeneron Pharmaceuticals Inc. and GSK Plc

Company Evaluation
Leading pharmaceutical companies such as Roche, Novartis, Merck & Co., Pfizer and AstraZeneca are strengthening their market presence through expanded biologics pipelines, targeted therapies, antibody engineering and investments in advanced monoclonal antibody treatments.

Innovative companies such as Regeneron and GSK are advancing novel antibody therapies and next-generation biologics, while expanding clinical pipelines and therapeutic applications across cancer, autoimmune and infectious diseases.

Growth Forecast Projected 2026:
The Global Monoclonal Antibody Therapeutics Market reached USD 283.3 Billion in 2025 and is projected to witness lucrative growth by reaching up to USD 817.0 Billion by 2033. The global monoclonal antibody therapeutics market is expected to exhibit a CAGR of 14.1% during the forecast period (2026-2033). Rising chronic diseases, expanding biologics pipelines, advancements in antibody engineering and increasing adoption of personalized medicine are expected to support market growth over the projected horizon.

Get 20% Complimentary Customization Within the Report:
https://www.datamintelligence.com/customize/monoclonal-antibody-therapeutics-market?sindhuri

M&A / Strategic Activity
Recent acquisitions, licensing transactions, and portfolio moves are reshaping the monoclonal antibody therapeutics landscape:

GSK - Acquisition of RAPT Therapeutics and long-acting anti-IgE antibody
In March 2026, GSK completed its acquisition of RAPT Therapeutics for an aggregate equity value of approximately $2.2 billion, adding ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylactic protection against food-allergy reactions. The program is designed around a potential 12-week dosing interval, compared with the 2-4-week injection frequency of existing anti-IgE treatment.

BioNTech - Biotheus acquisition strengthens bispecific antibody platform
BioNTech completed its acquisition of Biotheus in early 2025, securing full global rights to BNT327, an investigational PD-L1 × VEGF-A bispecific antibody, together with Biotheus' antibody-generation platform and bispecific antibody-drug conjugate capabilities. The transaction also added a research hub and biologics manufacturing facility in China, expanding BioNTech's ability to develop and manufacture antibody-based therapies.

Sanofi - Acquisition of Dren-0201 for targeted B-cell depletion
Sanofi acquired Dren Bio's DR-0201 program in 2025 for an upfront payment of $600 million, with up to $1.3 billion in potential development and launch milestones. DR-0201 is a CD20-directed bispecific myeloid-cell engager designed to recruit myeloid cells and drive targeted B-cell depletion through phagocytosis, creating a different mechanism from conventional B-cell-depleting antibodies.

Novo Nordisk - Global rights to MASP-3 monoclonal antibody zaltenibart
Novo Nordisk entered an asset purchase and license agreement with Omeros for global development and commercialization rights to zaltenibart (OMS906), a monoclonal antibody targeting MASP-3 in the alternative complement pathway. The transaction included $340 million in upfront and near-term milestone payments, with total potential payments of up to $2.1 billion, plus tiered royalties.

Johnson & Johnson - Firefly Bio acquisition adds degrader antibody-conjugate technology
In June 2026, Johnson & Johnson announced a $1 billion cash acquisition of Firefly Bio. The deal adds Firefly's FirelinkTM degrader antibody conjugate (DAC) platform, initially focused on KRAS-driven cancers, extending J&J's antibody-engineering strategy beyond conventional monoclonal and bispecific formats toward targeted intracellular protein degradation.

New Product/Antibody Launches & Deployments
Recent approvals and commercial developments are expanding the practical use of monoclonal, bispecific, and antibody-conjugate therapies:

Merck - ENFLONSIA establishes a single-dose RSV antibody option
In June 2025, the FDA approved ENFLONSIA (clesrovimab), a monoclonal antibody for prevention of RSV lower respiratory tract disease in neonates and infants entering their first RSV season. The product is administered as a single 105 mg intramuscular dose, providing an alternative antibody-based prevention strategy for infant RSV protection.

Janssen - Rybrevant Faspro moves amivantamab from IV to subcutaneous delivery
In December 2025, the FDA approved Rybrevant Faspro, a subcutaneous formulation of amivantamab combined with hyaluronidase, across the approved indications of intravenous amivantamab. The shift illustrates a broader move to redesign established antibody therapies around shorter and more convenient administration rather than relying exclusively on intravenous infusion.

GSK - Blenrep returns to the U.S. market with a new combination regimen
The FDA approved belantamab mafodotin (Blenrep) in October 2025 in combination with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior lines of therapy. The therapy is a BCMA-directed antibody-drug conjugate, combining antibody targeting with delivery of a cytotoxic payload.

Genmab - Epcoritamab expands into earlier-line follicular lymphoma treatment
The FDA approved epcoritamab (Epkinly) with lenalidomide and rituximab in November 2025 for relapsed or refractory follicular lymphoma and also granted traditional approval to epcoritamab monotherapy after two or more systemic treatment lines. The development reflects the movement of subcutaneous bispecific antibodies into combination regimens and earlier treatment settings.

AstraZeneca/Daiichi Sankyo - Datroway expands antibody-drug conjugate use in breast cancer
In May 2026, the FDA approved Datroway (datopotamab deruxtecan) for first-line treatment of certain patients with metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval further extends the use of TROP2-directed antibody-drug conjugates into earlier treatment settings.

Biocon Biologics - Pertuzumab biosimilar moves into European review
In September 2026, the EMA's CHMP issued a positive opinion for Pebrilzo (pertuzumab), a biosimilar to Perjeta for breast cancer. EMA identified it as the first biosimilar recommended following its tailored clinical approach, marking an important regulatory development for complex monoclonal-antibody biosimilar development.

R&D & Technological Advancements
Bispecific antibodies are moving beyond simple two-target designs
Development programs are increasingly combining immune-cell engagement with tumor or disease-target recognition. BNT327, for example, simultaneously targets PD-L1 and VEGF-A, while Sanofi's DR-0201 combines CD20 targeting with myeloid-cell engagement to drive B-cell depletion.

Antibody-drug conjugates are evolving toward targeted protein degradation
The Firefly Bio acquisition by Johnson & Johnson highlights a new direction in antibody engineering: using antibodies to selectively deliver protein degraders rather than relying only on conventional cytotoxic payloads. Firefly's FirelinkTM platform is being developed initially for KRAS-driven tumors.

Longer-acting antibodies are being designed around fewer treatment visits
GSK's ozureprubart program is being developed for potential 12-week dosing in food-allergy prevention, while Novo Nordisk's denecimig program has investigated once-monthly, every-two-week and weekly subcutaneous dosing in hemophilia A. These programs show how dosing frequency is becoming an explicit part of antibody-product design.

Subcutaneous delivery is becoming a major formulation strategy
Amivantamab's conversion from intravenous administration to a subcutaneous formulation with hyaluronidase demonstrates how antibody developers are addressing infusion burden. Similar administration strategies are already established for several bispecific antibodies, including subcutaneous epcoritamab.

AI and human-relevant testing are entering antibody development workflows
In April 2025, the FDA announced a plan to reduce, refine, and potentially replace animal testing requirements for monoclonal antibodies and other drugs. The agency specifically highlighted AI-based computational toxicity models, cell lines, and organoid-based testing as New Approach Methodologies that can contribute to IND submissions.

Biosimilar development is moving toward reduced clinical testing
The FDA proposed changes in October 2025 aimed at simplifying biosimilar development and reducing unnecessary clinical testing. By 2026, the agency's approved biosimilar list included antibody products such as rituximab, golimumab, pertuzumab, denosumab and others, increasing the number of biologic alternatives reaching the market.

Purchase This Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=monoclonal-antibody-therapeutics-market?sindhuri

Segments Covered in the Global Monoclonal Antibody Therapeutics Market:
By Product Type
The market is segmented into naked monoclonal antibodies, fusion proteins, antibody fragments, conjugates, and multi-specific antibodies. Naked monoclonal antibodies hold a major share due to their established use in cancer and autoimmune treatments. Conjugates and multi-specific antibodies are gaining traction due to targeted drug delivery and the ability to address multiple antigens or pathways.

By Application
The market is divided into cancer, autoimmune diseases, infectious diseases, and others. Cancer represents a major application due to the widespread use of monoclonal antibodies in targeted therapies. Autoimmune diseases are also significant, supported by growing biologic use, while infectious disease applications are expanding through antibody-based treatments and preventive therapies.

By Production Source
The market is segmented into human, humanized, chimeric, and others. Humanized monoclonal antibodies account for a significant share due to their reduced immunogenicity and established therapeutic use. Fully human antibodies are also gaining adoption through advances in antibody discovery and engineering.

By End User
The market is divided into hospitals, private clinics, and research institutes. Hospitals represent a major end-user segment due to the widespread use of monoclonal antibody therapies in oncology and autoimmune disease management. Private clinics and research institutes are also expanding their adoption across treatment and antibody development activities.

By Region
North America
North America is a leading market, supported by advanced healthcare infrastructure, high biologic adoption, and strong pharmaceutical and biotechnology research capabilities.

Europe
Europe is driven by growing adoption of targeted biologic therapies, established pharmaceutical research, and supportive healthcare systems.

Asia-Pacific
Asia-Pacific is expanding rapidly due to rising healthcare expenditure, increasing biologic adoption, expanding pharmaceutical manufacturing, and growing biotechnology investments across China, Japan, South Korea, and India.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.